34 results about "Multivalent Vaccine" patented technology

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The present invention provides a fusion protein and an expression vector for enhancing the soluble expression of norovirus antigens. More specifically, it provides a combination of diverse genotypes of norovirus antigen proteins and RID mutations that, when norovirus antigens are used as target proteins, fold most efficiently during the formation of recombinant fusion proteins, improve the soluble expression yield of the produced fusion proteins, and enhance the assembly efficacy and homogeneity of norovirus VLPs. Furthermore, by utilizing mutational RIDs, the present invention provides a method for rapidly and in large quantities producing not only GII.4 but also other diverse genotypes of norovirus VLPs in E. coli, thereby enabling the development of VLP-based multivalent vaccines containing a wider range of genotypes.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

The present invention relates to improved LAMP constructs comprising cancer antigens. Specifically, improved LAMP constructs comprising specific fragments of LAMP endodomain are provided to deliver cancer antigens to immune cells for enhanced processing. These LAMP constructs are useful in the treatment of diseases, in particular hyperproliferative disorders and / or cancer. The improved LAMP constructs, when administered to a subject, allow presentation of a correctly configured three-dimensional epitope for generating an immune response. The improved LAMP constructs may be multivalent molecules, and / or may be provided as part of multivalent vaccines containing two or more LAMP constructs. The improved LAMP constructs described herein can also be used to produce antibodies when administered to non-human vertebrates.

The present disclosure relates to methods for determining potency of multivalent RNA vaccines.

The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and / or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and / or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.

The invention belongs to the field of veterinary biological products, and particularly relates to an O-type foot-and-mouth disease strain containing a VP1 N133K mutation site and a construction method of the O-type foot-and-mouth disease strain. The invention provides an attenuated O-type foot and mouth disease virus mutant strain. Asparagine at the 133rd site of VP1 protein is mutated into lysine. The amino acid sequence of the mutated VP1 protein is as shown in SEQ ID NO: 2. The invention also provides a construction method of the attenuated O-type foot-and-mouth disease virus mutant strain, wherein N133K mutation is introduced by adopting a reverse genetics technology. The FMDV VP1 N133K mutant strain constructed by the method disclosed by the invention is beneficial to research on an FMDV attenuating mechanism. In addition, by reversely introducing VP1 N133K mutation, conservative epitopes can be screened or multivalent vaccines can be designed, and the cross protection capability is improved.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The present invention provides new canine Influenza H3N2 vaccines, including multivalent vaccines. The present invention provides an alphavirus RNA replicon particle that encodes a Canine Influenza (CIV) H3N2 hemagglutinin (HA) antigen. The present invention further provides methods of making and using the vaccines.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.

The invention discloses a rabbit pasteurella outer membrane vesicle trivalent vaccine and a preparation method thereof, and belongs to the technical field of multivalent vaccine preparation. According to the trivalent vaccine, outer membrane vesicle extracts from rabbit A type pasteurella multocida PmA HP-18, rabbit D type pasteurella multocida PmD HP-22 and rabbit F type pasteurella multocida PmF HP-11 are taken as antigens. The outer membrane vesicle trivalent vaccine provided by the invention contains a main outer membrane structure and periplasmic protein, has no life activity and good safety, and can effectively activate an immune system and generate protective immune response. A type pasteurella multocida, D type pasteurella multocida and F type pasteurella multocida can be prevented at the same time, and the three-prevention effect is achieved through one injection.

The application discloses a non-toxic genetically engineered toxoid molecule antigen vaccine based on a protective antigen functional domain structure and a preparation method and application thereof. It is determined that botulinum toxin and tetanus toxin both have two key protective antigen molecules, i.e. a receptor binding region Hc and a light chain-transmembrane region L-HN. Based on the important role of the functional domain in immunoprotective efficacy, a non-toxic genetically engineered toxoid or chimeric toxoid multivalent vaccine molecule is designed and prepared by using a biosynthesis technology. The vaccine has two important protective antigens of biological toxins, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency genetically engineered toxoid vaccine to replace formaldehyde inactivated toxoids for biological toxin prevention. The vaccine has important protective antigens of two different biological toxins, can produce protective efficacy against a plurality of different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.

The invention discloses a novel coronal virus mucosal immune vaccine based on a non-replicating vesicular stomatitis virus vector. The vaccine is delivered through a mucosal immunization way; the vaccine can be used in new crown vaccines, and can also be used in combination with other respiratory tract infection viruses such as respiratory syncytial vaccines (RSV) and influenza. At present, preparation of respiratory mucosa vaccines, especially multivalent vaccines, from replication-deficient VSV is not reported yet. According to the invention, safety and immunogenicity evaluation is carried out on the constructed VSVMT-S2P non-replicating recombinant VSV new crown vaccine in healthy narrative golden hamster and CP immunosuppression hamster models, and the VSVMT-S2P vaccine is found to be very safe in healthy animals; and the protein is highly safe in CP immunosuppressed hamsters. The VSVMT-S2P vaccine is subjected to single inoculation in the body of the narrative golden hamster through intranasal and intramuscular injection respectively, and it is proved that the VSVMT-S2P vaccine can effectively stimulate comprehensive immune response.

The invention relates to the technical field of preparation of tuberculosis vaccines, in particular to preparation and application of a VLP vaccine APEH + mi3 + AS01E for enhancing BCG immunity. The preparation method comprises the following steps: mixing Ag85B-mi3, PPE33-mi3, ESAT-6-mi3 and HSPX-mi3 to obtain multivalent nanoparticles, and fully emulsifying the multivalent nanoparticles and an AS01E adjuvant to obtain the VLP vaccine APEH + mi3 + AS01E. After the VLP vaccine APEH + mi3 + AS01E provided by the invention is immunized, strong Th1 type, Th2 type and Th17 type cellular immune responses are induced; after H37Rv challenge, the immune response of Th1 type, Th2 type and Th17 type cells induced by the multivalent mi3VLP vaccine is stronger than that of BCG, and the Mtb H37Rv infection resistance is slightly higher than that of BCG; the vaccine is used as a BCG reinforcing vaccine, and can effectively reinforce the short-term protective immune response of the BCG and the anti-tubercle bacillus protection effect.

In one aspect, the present application relates to immunogenic compositions comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharide and conjugates thereof. A multivalent vaccine can be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by recombinant bacteria comprising a wzz gene.

The present invention relates to recombinant HVT vectors expressing antigens of avian pathogens and uses thereof. In particular, the present invention provides recombinant herpesvirus comprising and expressing a turkey (HVT) vector of an antigen of an avian pathogen, compositions comprising the recombinant HVT vectors, multivalent vaccines comprising the recombinant HVT vectors and one or more wild-type viruses or recombinant vectors. The present invention also provides methods of vaccinating against multiple avian pathogens and methods of making the recombinant HVT vectors.

The invention belongs to the technical field of biology, and discloses a method for determining a multivalent antigen sequence of an anti-periodontitis red complex, which comprises the following steps: firstly, screening out key virulence factor antigens (FimA-II, RgpA, Msp and BspA) from three core pathogenic bacteria of the red complex: porphyromonas gingivalis, treponema denticola and fusisterone; then, independently cloning each antigen gene to a pUC57 cloning vector, constructing a single antigen recombinant plasmid, and avoiding intergene interference by designing a specific enzyme cutting site; and finally, through plasmid transformation, positive clone screening and double enzyme digestion verification, the plasmid quality is ensured. The obtained single antigen plasmid can be flexibly combined and used, is beneficial to subsequent multivalent vaccine development, and has the advantages of wide antigen coverage, high expression reliability, flexible construction strategy, easiness in industrialization and the like.

The present technology provides multivalent vaccine compositions and T cell compositions comprising viral antigens and related methods. In some embodiments, the viral antigen is an SARS-CoV-2 antigen. The vaccine composition and the T cell composition may include any one of a spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.

The invention provides a fusion protein for enhancing soluble expression of a norovirus antigen and an expression vector of the fusion protein. More specifically, provided is a combination of a plurality of genetic norovirus antigen proteins and RID mutations, in which folding occurs most effectively when a recombinant fusion protein is formed in the case where a norovirus antigen is used as a target protein, the soluble expression yield of the prepared fusion protein is improved, and the assembly efficacy and homogeneity of a norovirus VLP can be enhanced. In addition, the present invention provides a method that can produce GII.4 and other various genetic types of Norovirus VLPs in Escherichia coli in large quantities and rapidly using the mutant RID, thereby enabling the development of VLP-based multivalent vaccines comprising more genetic types.

The present invention, in embodiments, relates to a multivalent vaccine comprising a combination of two or more different monovalent Shigella oligosaccharide protein conjugates and an adjuvant. One of the vaccine components can be a Shigella sonnei oligosaccharide- protein conjugate and the other three can be Shigella flexneri oligosaccharide-protein conjugates, specifically, S. flexneri 2a, S. flexneri 3a and S. flexneri 6, respectively. All conjugates feature sOS components acting as surrogates of the heterogeneous Shigella surface polysaccharide antigens characteristic of each one of the selected Shigella serotypes. The multivalent vaccine of the present invention is made for the prevention and / or treatment of disease caused by Shigella, in particular S. sonnei and S. flexneri.

The present technology provides multivalent vaccine compositions and T cell compositions, and related methods, that include a viral antigen. In some embodiments, the viral antigen is a SARS-CoV-2 antigen. The vaccine compositions and T cell compositions may include each of a spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.

The present disclosure relates to multivalent vaccine compositions and their use in protecting pigs and progeny thereof from infection with E. coli, Clostridium spp, porcine parvovirus, and E. rhusiopathie, preferably with a new administration regimen for passive and active immunization of pigs and progeny thereof, as well as their use in protecting pigs and progeny thereof from infection with E. coli, Clostridium spp, porcine parvovirus, and E. rhusiopathie.

The present disclosure relates to a multivalent vaccine composition and its use in the protection against swine infections in a female pig and its progeny with a new scheme of administration.

The invention discloses a recombinant nucleic acid construct, a recombinant vaccinia virus, a vaccine composition and application thereof, and relates to the recombinant nucleic acid construct for preventing human adenovirus infection, the recombinant vaccinia virus prepared from the recombinant nucleic acid construct, the vaccine composition containing the virus, and preparation and application of the recombinant nucleic acid construct and the recombinant vaccinia virus. The technical problems that an existing multivalent vaccine is not uniform in immune effect and tedious in construction process are solved. The invention discloses a recombinant nucleic acid construct which comprises a vaccinia virus homologous recombination arm and an expression cassette unit located between the vaccinia virus homologous recombination arm. The expression cassette unit comprises human type-55, type-3 and type-7 adenovirus HEXON protein coding genes, the type-55 gene is reverse, and the type-3 and type-7 genes are forward. The recombinant vaccinia virus constructed by the method can realize stable co-expression of multivalent antigens, and is used for preparing multivalent vaccines for preventing infection of human type 3, type 7 and type 55 adenoviruses. The method is suitable for the fields of vaccine research and development, infectious disease prevention and control, viral vector technology platforms, recombinant protein or multivalent antigen expression technology and the like.

The invention discloses a recombinant serum type 3 duck adenovirus and a construction method and application thereof, the recombinant serum type 3 duck adenovirus replaces a non-structural protein gene ORF52 in the serum type 3 duck adenovirus with an exogenous target gene or inserts the exogenous target gene into the non-structural protein gene ORF52, and the nucleotide sequence of the non-structural protein gene ORF52 is shown as SEQ ID NO. 1. The recombinant serum type 3 duck adenovirus for expressing green fluorescent protein is constructed by targeting an exogenous gene EGFP to a non-structural protein gene ORF52 of the duck adenovirus type 3 by utilizing a gene editing technology, and the non-structural protein gene ORF52 is proved to be capable of serving as an insertion site of the exogenous gene, so that the recombinant serum type 3 duck adenovirus can be used as an insertion site of the exogenous gene. And a foundation is laid for developing a genetic engineering recombinant DAdV-3 multi-combined multivalent vaccine based on taking DAdV-3 as a virus vector.

The application discloses a gene modified non-toxic toxoid vaccine based on light chain-transmembrane region L-HN and receptor binding region Hc, and a preparation method and application thereof. The gene modified non-toxic novel toxoid vaccine molecule has two important protective antigen functional domains of a biological toxin, the N terminal of the vaccine molecule is the light chain-transmembrane region L-HN, and the C terminal is the receptor binding region Hc. The two protective antigen functional domains can be derived from the same biological toxin, can produce stronger protection than a single antigen, can produce strong complete protection at a low dose and a small number of immunization times, and can be used as a high-efficiency gene engineering toxoid vaccine to replace formaldehyde inactivated toxoid for biological toxin prevention. The two protective antigen functional domains can also be derived from different biological toxins, can protect against attacks of respective biological toxins, can produce protection against multiple different toxin biological agents, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention.